Lab
Megamed Clinical Laboratories INC
Megamed Clinical Laboratories INC was paid $333K by Medicaid between Jan 2018 and Oct 2023, across 41 billing codes. Its largest line is 87491, Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe — 38% of everything it billed.
33Billing provider infoMEGAMED CLINICAL LABORATORIES INC
RESEDA, CA 91335
RESEDA, CA 91335
33aNPI1992895643assigned 10/13/2006
33bProvider typeClinical Medical Laboratory
28Total paid$333K
24GClaims15,918
24DCodes billed41
24AFirst – last monthJan 2018 – Oct 2023
Compared with peers
Next to other Clinical Medical Laboratory providers in California
Rank by total paid#260 of 561
Median peer was paid$222K
This provider vs. median1.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 15,091 | $331K | |
| 2019 | 562 | $2K | |
| 2020 | 29 | $575.53 | |
| 2023 | 236 | $19.05 |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 38% | 4,088 | 4,088 | $127K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 38% | 4,088 | 4,088 | $127K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 18% | 2,914 | 2,914 | $59K |
| 86592 | 3.3% | 2,908 | 2,908 | $11K | |
| 87486 | <1% | 67 | 67 | $1K | |
| 87507 | <1% | 36 | 36 | $1K | |
| 80074 | <1% | 20 | 20 | $738.16 | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 17 | 15 | $550.00 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 139 | 135 | $490.40 |
| 80061 | Lipid panel | <1% | 96 | 93 | $478.72 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 60 | 60 | $438.94 |
| 86762 | <1% | 36 | 36 | $428.42 |
29 more codes
| 80053 | Comprehensive metabolic panel | <1% | 114 | $411.13 |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 12 | $349.55 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 59 | $343.18 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 19 | $312.34 |
| 87340 | <1% | 36 | $295.56 | |
| 84480 | <1% | 46 | $259.63 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 87 | $248.12 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 41 | $212.84 |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 15 | $211.20 |
| 84439 | <1% | 56 | $185.05 | |
| 81000 | <1% | 109 | $170.91 | |
| 87631 | <1% | 55 | $161.07 | |
| 86708 | <1% | 18 | $141.82 | |
| 86704 | <1% | 18 | $136.50 | |
| 82043 | <1% | 41 | $134.08 | |
| 86706 | <1% | 18 | $119.84 | |
| 82570 | <1% | 38 | $97.32 | |
| 82150 | <1% | 38 | $93.30 | |
| 87581 | <1% | 67 | $90.85 | |
| 87081 | <1% | 15 | $76.65 | |
| 83690 | <1% | 36 | $65.65 | |
| 87210 | <1% | 13 | $46.28 | |
| 84550 | <1% | 15 | $25.58 | |
| 80305 | <1% | 236 | $19.05 | |
| 85651 | <1% | 12 | $17.04 | |
| 0100U | 0% | 86 | $0.00 | |
| 86003 | 0% | 12 | $0.00 | |
| 0097U | 0% | 98 | $0.00 | |
| 87541 | 0% | 39 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMOTAMEDI, SHAPOUR (PRESIDENT)